Morquio syndrome A
Other Names for this Disease
- Galactosamine-6-sulfatase deficiency
- GALNS deficiency
- Morquio A disease
- MPS 4A
- MPS IVA
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
- Project OrphanAnesthesia is a project whose aim is to create peer-reviewed, readily accessible guidelines for patients with rare diseases and for the anesthesiologists caring for them. The project is a collaborative effort of the German Society of Anesthesiology and Intensive Care, Orphanet, the European Society of Pediatric Anesthesia, anesthetists and rare disease experts with the aim to contribute to patient safety.
- ClinicalTrials.gov lists trials that are studying or have studied Morquio syndrome A. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
Medical ProductsThe medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.
|Generic Name||elosulfase alfa|
(BioMarin Pharmaceutical Inc.)
The FDA has approved this product to be used in this manner.
|Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)|
|More Information about this product||Drug Information Portal|